Evidence map›Paper›PMID 40650935›Full record

ArticleOncoimmunology2025

How macrophages use extracellular calreticulin to chase their prey.

Liwei Zhao, Peng Liu, Oliver Kepp, Guido Kroemer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Liwei ZhaoCentre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, Equipe labellisée par la Ligue contre le cancer, Institut Universitaire de France, Paris, France.ORCID 0000-0001-5077-327X
Peng LiuCentre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, Equipe labellisée par la Ligue contre le cancer, Institut Universitaire de France, Paris, France.ORCID 0000-0002-1682-9222
Oliver KeppCentre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, Equipe labellisée par la Ligue contre le cancer, Institut Universitaire de France, Paris, France.ORCID 0000-0002-6081-9558
Guido KroemerCentre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, Equipe labellisée par la Ligue contre le cancer, Institut Universitaire de France, Paris, France.ORCID 0000-0002-9334-4405

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent findings reveal that macrophages actively control clearance by desialylating target cells via NEU1 and releasing cathepsin-cleaved calreticulin (CALR) to mark them for phagocytosis. This uncovers a dual role for CALR as immune activator or repressor, depending on its form and context, with distinct implications for cancer immunity.

Indexed as

CalreticulinMacrophagesNeoplasmsPhagocytosisAnimalsHumansCalreticulinAsialoglycanscancercell stressimmunotherapy

Identifiers

PMID40650935
PMCPMC12258218

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.